HARMONIUM PHARMA

About HARMONIUM PHARMA

Harmonium Pharma is an Italian healthcare company focused on diabetes, with products to help patients in the daily management of diabetes and prevention of its complications.

Medical devices, food supplements and dermocosmetics specific for people with diabetes are positioned in the Diabetic Corner, a unique concept available in the pharmacies/retail channel. 

Harmonium Pharma partners with several companies worldwide and looks for additional partners interested in an exclusive distribution of these diabetes products in the respective countries.

  • IT
  • 2017
    On CPHI since
  • 1 - 24
    Employees
Company types
Distributor/Import Export
Contact info

Products from HARMONIUM PHARMA (3)

  • The Diabetic Corner

    Product "The Diabetic Corner"

    The first space dedicated to people suffering from diabetes, The Diabetic Corner is the innovative opportunity for the pharmacies dedicated to the daily management of diabetes and prevention of its complications. Launched in Italy, The Diabetic Corner includes specific solutions and products to meet need...
  • Glucosprint Plus

    Product Glucosprint Plus

    Glucosprint Plus® is a quick and efficient solution, useful to people with diabetes, to treat hypoglycemia . It contains dextrose, vitamin B1 and manganese that contribute to a normal energy-yielding metabolism.

    Features
    • Clinical study on the treatment of hyp...
  • Colipex

    Product Colipex

    Colipex has an emollient and soothing effect improving the skin elasticity. It also has a moisturizing and nourishing effect on the skin.

    Features • Clinical study on Elastargene 3C helps to improve glycated haemoglobin in children and adolescents with type using insulin pump therapy, • Astring...

HARMONIUM PHARMA Resources (1)

  • News Colipex: results of clinical study presented in Stockholm

    Good news for diabetic people comes from a study conducted by Dr. Andrea Scaramuzza of the Luigi Sacco Hospital (Milan), the results of which were presented at the 51st EASD (European Association for the Study of Diabetes) Congress in Stockholm.